A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311 · TroFuse-015 Phase 3Active, not recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 473 (actual)
- Start date
- 3 May 2024
- Primary completion
- 19 Oct 2026 (actual)
- Study completion
- 6 May 2027
- Last update posted
- 22 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Single
- Arms
- 2
Interventions
- Sacituzumab tirumotecan Biological
- Trifluridine-Tipiracil Drug
- Irinotecan Drug
- Paclitaxel Drug
- Docetaxel Drug
- Rescue medications Drug
- Supportive care measures Drug
Conditions and primary outcome
- Gastroesophageal Cancer
Primary outcome
Overall Survival (OS) (Up to ~ 31 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06356311.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06356311 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.